Title: An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
2055041-02-4 | M-Peg3-sulfone-peg4-propargyl | AA019E2Y | MFCD29918252
69502-27-8 | 3,6,9,12,15,18-Hexaoxaicosane-1,20-diyl bis(4-methylbenzenesulfonate) | AA019E79 | MFCD06292255
2112738-60-8 | N-Mal-n-bis(peg4-nhs ester) | AA019EBU | MFCD29912654
344402-35-3 | ROX NHS ester, 5-isomer | AA019EFN
862647-09-4 | (R)-2-Benzhydryloxirane | AA019EJ5 | MFCD30471790
1310381-24-8 | Racemic-(3ar,5s,7ar)-tert-butyl 5-(hydroxymethyl)hexahydropyrano[3,2-b]pyrrole-1(2h)-carboxylate | AA019ELT | MFCD28657279
1823807-74-4 | 6-Benzyl-2-(tert-butoxycarbonyl)-2,6-diazaspiro[3.4]octane-8-carboxylic acid | AA019EPC | MFCD24369442
1296201-73-4 | 6-bromo-N-(3-methoxybenzyl)-1H-indole-2-carboxamide | AA019ESD | MFCD15807908
18522-95-7 | Ethyl 2-(methylamino)-2-oxoacetate | AA019EVT | MFCD02859930
1404115-37-2 | 2-Bromo-6-(difluoromethoxy)benzaldehyde | AA019EYZ | MFCD29059417